Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569321 | 1.00 | ATM (0.34) | ATMRIPK1DPP4DPP8DPP9 | |
| SCHEMBL20973729 | 1.00 | ATM (0.34) | ATMRIPK1DPP4DPP8DPP9 | |
| SCHEMBL4041770 | 1.00 | ATM (0.34) | ATMRIPK1DPP4DPP8DPP9 | |
| SCHEMBL18298229 | 0.87 | MMP2 (0.33) | — | |
| SCHEMBL19550932 | 0.87 | FKBP1A (0.30) | — | |
| SCHEMBL4972513 | 0.86 | FKBP1A (0.33) | DUT | |
| SCHEMBL4214203 | 0.86 | FKBP1A (0.33) | DUT | |
| SCHEMBL2957842 | 0.86 | FKBP1A (0.33) | DUT | |
| SCHEMBL4274093 | 0.85 | CYP1A2 (0.40) | — | |
| SCHEMBL5195675 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463728-B1 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | disclosed |
| US-7432267-B2 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMAPNY (US) | 2008-10-07 | — | — | US | disclosed |
| US-7001911-B2 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20050282813-A1 | Fused cyclic modulators of nuclear hormone receptor function | SALVATI MARK E | 2005-12-22 | — | — | US | disclosed |
| US-20050256048-A1 | Selective androgen receptor modulators and methods for their identification, design and use | SALVATI MARK E | 2005-11-17 | — | — | US | disclosed |
| US-6960474-B2 | Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040077606-A1 | Fused cyclic modulators of nuclear hormone receptor function | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-04-22 | — | — | US | disclosed |
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-19 | — | — | US | disclosed |
| US-20020173445-A1 | Selective androgen receptor modulators and methods for their identification, design and use | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256048-A1 | Selective androgen receptor modulators and methods for their identification, design and use | AR, FSHR, LHCGR | ATM 1750/4885RIPK1 2128/4885DPP4 3329/4885 |
| US-20050282813-A1 | Fused cyclic modulators of nuclear hormone receptor function | NR2C2, NR0B2, NR0B1 | ATM 2162/4885RIPK1 1974/4885DPP4 4634/4885 |
| US-20020173445-A1 | Selective androgen receptor modulators and methods for their identification, design and use | AR, FSHR, LHCGR | ATM 1750/4885RIPK1 2128/4885DPP4 3329/4885 |
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR3C1 | ATM 1835/4885RIPK1 2400/4885DPP4 3752/4885 |
| US-20040077606-A1 | Fused cyclic modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR3C1 | ATM 1835/4885RIPK1 2400/4885DPP4 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.